A familiar theme as of late. The chart is self-explanatory, depicting a violated lower trend line and corresponding support levels (S-1 - S-4). In the event the stock closes below that psychological $1.00 mark, selling will likely accelerate. For reference only. As always, these are only my opinions and not investment advice.
Drug for female sexual dysfunction (FSD). Bremelanotide is an on-demand melanocortin receptor agonist that acts in the central nervous system to positively impact sexual response. The treatment is being developed for the large FSD indication that includes up to 20% of women in the US, but for which there is no FDA-approved drug treatment.
"Palatin's bremelanotide...
